Nuvation Bio Inc.
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, …
Biotechnology
US, New York [HQ]
Revenue Breakdowns
Segment Analysis Beta
The financial segments are sourced from the SEC' 10-K statement.Revenue By Top Segments
Nuvation Bio Inc. can't present it's sankey chart.
Historical Revenue By Segment
Last 3Y, in million USDNuvation Bio Inc. can't present revenue by segment